Company Biosynex

Equities

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Sector Diagnostic & Testing Substances

Real-time Euronext Paris Other stock markets 03:12:32 2024-07-09 am EDT			5-day change	1st Jan Change
3.23 ^EUR	-2.56%		+10.62%	-61.32%

May. 28	Biosynex: obtains CE markings under the new IVDR regulations	CF
May. 13	Biosynex: Oren Bitton appointed Chief Operating Officer	CF

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas:

- manufacturing of diagnosis tests for own account;

- sale of diagnosis tests supplied by other manufacturers of semi-finished products;

- research and development services for third party;

- sale of licenses;

- sale of biological reagents.

At the end of 2023, the group had one production site located in France.

France accounts for 56.5% of net sales.

Number of employees: 569

EUR in Million	2022	Weight	2023	Weight	Delta
Professionals 58.9 %	121	61.5 %	55	58.9 %	-54.79%
General Public 41.1 %	76	38.5 %	38	41.1 %	-49.47%

EUR in Million	2022	Weight	2023	Weight	Delta
France 56.5 %	120	61.1 %	53	56.5 %	-56.32%
International 43.5 %	76	38.9 %	40	43.5 %	-47.12%

Managers	Title	Age	Since
Thomas Lamy FOU	Founder	-	05-03-14
Larry Abensur CEO	Chief Executive Officer	69	05-03-14
Thierry Paper FOU	Founder	61	05-03-14
Elie Fraenckel DFI	Director of Finance/CFO	-	12-10-31
Oren Bitton SAM	Sales & Marketing	-	10-12-31

Members of the board	Title	Age	Since
Thierry Paper FOU	Founder	61	05-03-14
Thomas Lamy FOU	Founder	-	05-03-14
Larry Abensur CEO	Chief Executive Officer	69	05-03-14
Elie Fraenckel DFI	Director of Finance/CFO	-	12-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	10,760,870	3,982,210 ( 37.01 %)	316,993 ( 2.946 %)	37.01 %

Name	Equities	%	Valuation
Larry Abensur 41.16 %	4,429,309	41.16 %	13 M €
Thomas Lamy 10.81 %	1,162,980	10.81 %	4 M €
Thierry Paper 3.624 %	389,988	3.624 %	1 M €
BIOSYNEX 0.9940 %	106,966	0.9940 %	324 433 €
Sunny Asset Management SA 0.6970 %	75,000	0.6970 %	227 479 €
Mandarine Gestion SA 0.3811 %	41,006	0.3811 %	124 373 €

Name	Equities	%	Valuation
BIOSYNEX 0.99%	106,966	0.99%	324,433 $

Biosynex SA

22, boulevard Sebastien Brant

67400, Illkirch-Graffenstaden

+33 3 88 78 78 87

http://www.biosynex.com

Name	Category and Sector
Biosynex Swiss SA
THERADIAG	Medical Specialties

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOSYNEX	-61.32%	38.65M
BIOMÉRIEUX	-8.00%	11.78B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-22.07%	6.59B
LANTHEUS HOLDINGS, INC.	+27.13%	5.46B
AUTOBIO DIAGNOSTICS CO., LTD.	-24.14%	3.45B
ANDON HEALTH CO., LTD.	+4.11%	2.5B
MYRIAD GENETICS, INC.	+31.97%	2.29B
10X GENOMICS, INC.	-67.03%	2.21B
VITROLIFE AB	-12.53%	2.2B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-17.96%	1.59B

Diagnostic & Testing Substances